Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This is a multicentric, phase IV study. In this study patients that are receiving an
antineoplastic treatment and that have been diagnosed with venous thromboembolism will
receive edoxaban as per clinical practice. Edoxaban will be administered according to summary
of product characteristics. Patients will receive 6 to 12 months of treatment with edoxaban
administered orally. The thromboembolic event will be monitored as per local clinical
practice. In this study patients will be evaluated at baseline, at the beginning of therapy
with edoxaban, after 1 month (+/- 7 days), after 3, 6 and 12 months (+/- 3 weeks). During
these visits, patients will be provided of a diary in which they should report drug intake
and interruptions and quality of life questionnaires.